"Under the Radar" is a daily feature that uncovers little-known companies worthy of investors' consideration. Check in at 5 every morning to find out about stocks that tend to beat their bigger brethren.

Aging Baby Boomers are going to push demand for medical products and services for the next 20 years. Investors seeking a health care play should look at companies poised to benefit from the trend.

Bio-Reference Laboratories ( BRLI) is a little-known provider of lab services with a strong track record, stable financial position and compelling growth prospects. The Elmwood Park, N.J.-based company helps medical professionals in Greater New York City detect, diagnose and monitor diseases.

The company has increased profits for 10 straight quarters. Its fiscal second-quarter revenue rose 16% to a record $87 million as net income increased 35% to $4.6 million and earnings per share climbed 32% to 33 cents. Operating margin gained two percentage points to 10% and net margin inched up to 5%.

Bio-Reference's cash balance has increased 32% to $13 million from the year-earlier quarter, which translates to a high quick ratio of 1.8. The company has kept its debt in check with only $37 million of long-term obligations on its balance sheet and just $400,000 in quarterly interest expenses. A debt-to-equity ratio of 0.3 confirms the modest leverage.

Bio-Reference has strong growth potential in women's health and genetic testing. The company runs a national lab that focuses on sexually transmitted diseases in women. Its GeneDX subsidiary, which tests for rare genetic diseases, will likely expand as scientists map the human genome and treatments become more tailored to individual patients.

With a market capitalization of about $420 million, Bio-Reference isn't a brand-name stock. It's up 15% this year, outperforming the Dow Jones U.S. Health Care Index, which includes Johnson & Johnson ( JNJ) and Pfizer ( PFE). The shares have risen 13% annually, on average, during the past three years, while the benchmark has lost 3.3%.

Consequently, Bio-Reference is no longer a cheap investment. The stock trades at a price-to-earnings ratio of about 23, which is a 65% premium to its peer group. The company also doesn't pay dividends.

Still, the firm expects to increase revenue by 15% and net income by 20% this year. We rate Bio-Reference "buy."

If you liked this article you might like

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)